Clinical Trial Update: Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT [Phase 1]

View source ↗

Summary

Phase 1 dose-finding study of vedolizumab for graft-versus-host disease in participants undergoing allogeneic hematopoietic stem cell transplantation has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Stem Cell Transplantation
• Graft-versus-host Disease

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 | Status: COMPLETED | Results posted: 2019-08-26